CAJ | 학술논문

目的探讨丝氨酸/苏氨酸蛋白激酶1(PLK1)在前列腺癌中的表达及其临床意义.方法应用免疫组化PV-9000两步法检测PLK1在51例前列腺癌组织,35例良性前列腺增生组织中的表达.结果 PLK1在前列腺癌组织中呈过表达,与良性前列腺增生组织相比,差异十分显著(P＜0.05).在前列腺癌组织高、中、低分化组的表达均有显著性差异(P＜0.05),在C～D期的表达明显高于A～B期的表达,有显著性差异(P＜0.05)；其表达与病理Glease评分呈正相关(r=0.622,P＜0.01),与临床分期呈正相关(r =0.522,P＜0.01),与年龄、术前PSA无明显相关性.结论 PLK1在前列腺癌中高表达,与肿瘤的增值活性相关,在前列腺癌的发生发展中起重要作用,可能成为治疗前列腺癌的一个新的理想靶点.
목적 탐토사안산/소안산단백격매1(PLK1)재전렬선암중적표체급기림상의의.방법 응용면역조화PV-9000량보법검측PLK1재51례전렬선암조직,35례량성전렬선증생조직중적표체.결과 PLK1재전렬선암조직중정과표체,여량성전렬선증생조직상비,차이십분현저(P＜0.05).재전렬선암조직고、중、저분화조적표체균유현저성차이(P＜0.05),재C～D기적표체명현고우A～B기적표체,유현저성차이(P＜0.05)；기표체여병리Glease평분정정상관(r=0.622,P＜0.01),여림상분기정정상관(r =0.522,P＜0.01),여년령、술전PSA무명현상관성.결론 PLK1재전렬선암중고표체,여종류적증치활성상관,재전렬선암적발생발전중기중요작용,가능성위치료전렬선암적일개신적이상파점.
Objectives To explore the expressions of PLK1 and its clinical significance in prostatic carcinoma.Methods PLK1 is detected in 51 prostatic carcinoma and 35 benign prostatic hyperplasia tissue by immunohistochemical PV-9000 two steps method.Results There is a over expression of PLK1 in prostate carcinoma and there is significant difference between the two groups(P ＜0.05).The positive rate of PLK1 in poorly differentiated groups and the moderately differentiated groups are higher than well-differentiated groups(P ＜ 0.05),there also is significant difference between poorly differentiated groups and the moderately differentiated groups (P ＜ 0.05).The positive rate in C ～ D period is higher than that of A ～ B period,and there is significance difference between the two groups (P ＜ 0.05).There is no significant relationship between PLK1 positive rate and age,also there is no significant relationship between PLK1 positive rate and the size of tumor.There is positive correlation between PLK1 positive rate and Gleason score,as well as clinical stage.Conclusions The high expression of PLK1 in prostate carcinoma has a relationship with the proliferous activity.It plaies a importante role in the oncogenesis and the development of the prostate carcinoma,and it may become a new ideal target in treating prostate carcinoma.